Battered Gemphire shares soar on new triglyceride data, but there’s a lot left to prove
Less than a year after Gemphire shares $GEMP were doused by poor LDL numbers for its lead drug gemcabene, investors rallied to the cause with a fresh dose of positive Phase IIb results for the same therapy among patients with severe hypertriglyceridemia — or at least the way they defined the disease.
On Thursday evening the stock more than doubled in value after the biotech reported that their treatment — at the high dose — was able to significantly reduce the amount of triglycerides in the blood relative to a placebo. The key readout for the company:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
